Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Oncocyte’s Nashville CLIA lab now offers the Therascreen RGQ KRAS test Addition of the Therascreen RGQ KRAS test strengthens Oncocyte’s one-stop shop offering for lung cancer treatment decisions ...
-
-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer...
-
Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s...
-
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
IRVINE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the...
-
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional...
-
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
-
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection ...